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Background: Familial Cerebral Cavernous Malformation type 1 (CCM1) is an autosomal dominant disease
caused by mutations in the Krev Interaction Trapped 1 (KRIT1/CCM1) gene, and characterized by multiple
brain lesions. CCM lesions manifest across a range of different phenotypes, including wide differences in
lesion number, size and susceptibility to intracerebral hemorrhage (ICH). Oxidative stress plays an im-
portant role in cerebrovascular disease pathogenesis, raising the possibility that inter-individual varia-
bility in genes related to oxidative stress may contribute to the phenotypic differences observed in CCM1
disease. Here, we investigated whether candidate oxidative stress-related cytochrome P450 (CYP) and
matrix metalloproteinase (MMP) genetic markers grouped by superfamilies, families or genes, or ana-
lyzed individually inﬂuence the severity of CCM1 disease.
Methods: Clinical assessment and cerebral susceptibility-weighted magnetic resonance imaging (SWI)
were performed to determine total and large (Z5 mm in diameter) lesion counts as well as ICH in 188
Hispanic CCM1 patients harboring the founder KRIT1/CCM1 ‘common Hispanic mutation’ (CCM1–CHM).
Samples were genotyped on the Affymetrix Axiom Genome-Wide LAT1 Human Array. We analyzed 1,122
genetic markers (both single nucleotide polymorphisms (SNPs) and insertion/deletions) grouped by CYP
and MMP superfamily, family or gene for association with total or large lesion count and ICH adjusted for
age at enrollment and gender. Genetic markers bearing the associations were then analyzed individually.
Results: The CYP superfamily showed a trend toward association with total lesion count (P¼0.057) and
large lesion count (P¼0.088) in contrast to the MMP superfamily. The CYP4 and CYP8 families were
associated with either large lesion count or total lesion count (P¼0.014), and two other families (CYP46
and the MMP Stromelysins) were associated with ICH (P¼0.011 and 0.007, respectively). CYP4F12
rs11085971, CYP8A1 rs5628, CYP46A1 rs10151332, and MMP3 rs117153070 single SNPs, mainly bearing
the above-mentioned associations, were also individually associated with CCM1 disease severity.
Conclusions: Overall, our candidate oxidative stress-related genetic markers set approach outlined CYP
and MMP families and identiﬁed suggestive SNPs that may impact the severity of CCM1 disease, in-
cluding the development of numerous and large CCM lesions and ICH. These novel genetic risk factors ofr Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
tion; CHM, common hispanic mutation; ICH, intracerebral hemorrhage; CYP, cytochrome P450; MMP, matrix me-
xtracellular matrix; NVU, neurovascular unit; BBB, blood–brain barrier; SNP, single nucleotide polymorphism; AA,
; EET, epoxyeicosatrienoic acids; 24-OHC, 24(S)-hydroxycholesterol; 27-OHC, 27-hydroxycholesterol; 25-OH-D3, 25-
min D3
iological Sciences, University of Torino, Regione Gonzole, 10, 10043 Orbassano, Torino, Italy.
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provide better options for disease prevention and treatment.
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Cerebral Cavernous Malformation (CCM) is a major cere-
brovascular disease consisting of closely clustered, abnormally
dilated and leaky capillary malformations, which can be single or
multiple (even hundreds), ranging in size from a few millimeters
to a few centimeters [1–4]. Despite their high prevalence in the
general population (0.3–0.5%), only approximately 30% of people
with CCM lesions will eventually develop clinical symptoms, in-
cluding headaches, focal neurological deﬁcits, seizure, stroke, and
fatal intracerebral hemorrhage (ICH) [5]. Symptomatic disease
usually occurs between the 2nd and 5th decades of life, although it
has been described in all age groups, including young children [3].
Although advances have been made toward understanding the
natural history and pathogenic mechanisms of CCM disease, the
clinical behavior in individual patients, including the development
of numerous and large symptomatic lesions and the risk of serious
complications such as ICH, is highly unpredictable [6]. Identiﬁca-
tion of modiﬁable risk factors of prognostic value associated with
clinical severity of CCM disease is therefore needed to ultimately
provide better options for disease prevention and treatment.
CCM disease may arise sporadically or can be inherited as an
autosomal dominant condition with incomplete penetrance and
variable expressivity. The familial form has been linked to loss-of-
function mutations in any of three known CCM genes (KRIT1/
CCM1,MGC4607/CCM2 and PDCD10/CCM3), and is characterized by
the presence of multiple CCM lesions whose number, size and
susceptibility to ICH vary widely even among carriers of the same
gene mutation [7,8]. The origin of this variability is still largely
unknown, although it is likely that multiple factors contribute to
CCM disease severity, including genetic, environmental and life-
style risk factors. Consistently, we have recently reported the in-
ﬂuence of cardiovascular risk factors [7], and inﬂammatory and
immune response genetic factors [8] on the severity of familial
CCM1 disease in a cohort of Hispanic CCM patients, all carrying the
founder KRIT1/CCM1 Q455X ‘Common Hispanic Mutation’ (CCM1–
CHM).
Comprehensive studies in CCM animal models have revealed a
causal link between loss-of-function of CCM genes and the de-
velopment of vascular malformations mimicking human CCM le-
sions [9–13]. However, experiments in inducible, endothelial-
speciﬁc knockout mouse models have clearly demonstrated that
lesion development is highly restricted, both spatially and tem-
porally, despite the pan-endothelial deletion of CCM genes, sug-
gesting that the homozygous loss of CCM genes is not fully sufﬁ-
cient to induce CCM lesions, and raising the possibility that addi-
tional events occurring locally within the neurovascular micro-
environment, including stress events, are necessary to trigger CCM
lesion formation [14–16]. Among the microenvironmental stress
events that might account for a sort of environmental second hit,
triggering CCM lesion formation, there is oxidative stress. This may
occur as a consequence of an endogenous imbalance between
molecular mechanisms of production and scavenging of reactive
oxygen species (ROS), as well as by exogenous oxidative insults,
including cell exposure to xenobiotics, ionizing radiations, or pro-
oxidant factors that may be released locally following in-
ﬂammatory responses, impaired neurovascular coupling, and
ischemia-reperfusion events [17,18]. Remarkably, there is now a
wealth of evidence indicating that oxidative stress is a major cause
of vascular remodeling and neurovascular unit (NVU) dysfunctionassociated with cerebrovascular diseases [17,19,20]. Indeed, oxi-
dative stress has been clearly implicated in major molecular and
cellular dysfunctions related to CCM disease, including destabili-
zation of VE-cadherin-mediated endothelial cell-cell junctions and
blood–brain barrier (BBB) integrity, increased β1 integrin activa-
tion, reduced cells’ ability to maintain a quiescent state, and in-
creased vascular permeability and angiogenic activity [18,19,21–
23], suggesting that it might signiﬁcantly contribute in driving the
onset and progression of CCM disease. Consistently, considerable
evidence from both in vitro and in vivo studies demonstrates that
CCM proteins, including KRIT1/CCM1, CCM2 and PDCD10/CCM3,
are implicated in the modulation of various redox-sensitive sig-
naling pathways and cellular responses to oxidative stress
[16,22,24–29]. In particular, original ﬁndings indicated that KRIT1
is involved in the maintenance of intracellular ROS homeostasis
through the modulation of master regulators of cellular responses
to oxidative stress, including FoxO1 and SOD2, which prevent the
accumulation of superoxide anions produced at the mitochondrial
electron transport chain and consequent mitochondrial and cel-
lular dysfunctions [24]. Since then, accumulating evidence has
provided strong support for a role of oxidative stress in CCM pa-
thogenesis, demonstrating that CCM proteins play an important
role in limiting pro-oxidant and pro-inﬂammatory pathways and
mechanisms, including c-Jun-dependent pathways [22] and de-
fective autophagic removal of dysfunctional mitochondria [28].
Furthermore, there is also evidence that compounds endowed
with antioxidant properties are effective in rescuing major disease
phenotypes associated with loss-of-function of CCM genes
[16,22,24,26,27], including decreased endothelial barrier function
and increased lesion burden in a mouse model of CCM disease
[16].
While pointing to a novel pathogenic mechanism whereby the
loss-of-function of CCM proteins sensitize vascular cells to local
oxidative stress events, these ﬁndings raised also the possibility
that inter-individual variability in susceptibility to oxidative stress
may contribute to CCM disease pathogenesis [29].
Notably, several genes encoding proteins involved in ROS me-
tabolism and vascular responses to oxidative stress are char-
acterized by single nucleotide polymorphisms (SNPs) that confer
substantial inter-individual variability in susceptibility to various
oxidative stress-related pathologies, including vascular diseases
[30–33], suggesting that inter-individual variation in polymorph-
isms of genes related to oxidative stress responses might con-
tribute to the phenotypic differences characterizing the familial
form of CCM disease.
In particular, among several polymorphic candidate genes re-
lated to oxidative stress that might be associated with CCM disease
development and severity, we focused our analysis on the highly
polymorphic cytochrome P450 (CYP) and matrix metalloprotei-
nase (MMP) genes. Indeed, genetic variants in these genes have
been shown to be signiﬁcant indicators for susceptibility to the
most severe forms of well-established oxidative stress-related
diseases [34,35].
The human CYP superfamily comprises 57 genes encoding for
monooxygenases performing a variety of oxidation reactions im-
plicated in important physiopathological processes [36]. High le-
vels of CYP activity are associated with increased oxygen radical
formation and cellular oxidative stress, which can damage cellular
macromolecules, including proteins, lipids and DNA [37,38]. Im-
portantly, whereas most CYP enzymes exhibit a large variability in
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population and in a given individual under various conditions [39],
compelling evidence supports the expression of these enzymes by
BBB endothelial cells and astrocytes associated with cerebral mi-
crovessels [40–43]. Indeed, it has been demonstrated that varia-
tions in the expression and activity of CYPs can inﬂuence the local
regulation of cerebral blood ﬂow and vascular homeostasis, and
contribute to cerebrovascular diseases [44,45]. Consistently, ge-
netic polymorphisms in several CYPs have been associated with
inter-individual differences in susceptibility to various vascular
and neurological disorders [39,46–48].
The human matrix metalloproteinase (MMP) superfamily
comprises 24 genes encoding proteolytic enzymes that degrade
various components of the extracellular matrix (ECM) in both
physiological and pathological processes, mediating ECM re-
modeling and supplying bioactive molecules that impact cellular
function. In vascular tissues, including cerebral microvessels, the
expression and activity of MMPs are regulated by major drivers of
vascular remodeling, such as ROS [49] and oxidative stress [50,51],
and may contribute to oxidative stress-mediated vascular dys-
functions and BBB breakdown in cerebrovascular diseases [52,53].
Indeed, once activated, MMP enzymes mediate the proteolytic
degradation of endothelial basal lamina components and the re-
lease of ECM-bound latent bioactive molecules, including pro-an-
giogenic growth factors and cytokines such as VEGF and TGF-β1,
thus playing a pivotal role in vascular remodeling and BBB rupture
induced by various physiological stimuli and pathological stresses,
and contributing to oxidative stress-related signaling events
[49,54–56]. Consistently, polymorphisms in some MMP genes are
important genetic risk factors inﬂuencing inter-individual differ-
ences in susceptibility to the onset and/or severity of various
vascular diseases, including cerebrovascular diseases [57–62].
Overall, our analysis of polymorphic candidate genes related to
oxidative stress identiﬁed suggestive SNPs in CYP and MMP genes
that showed a statistically signiﬁcant association with phenotypic
markers of CCM1 disease severity, indicating that variation in
these genes may contribute to inter-individual differences in sus-
ceptibility to CCM disease.1
22. Methods
2.1. Study population
The study sample comprised 188 CCM1 subjects, all conﬁrmed
carriers of the KRIT1/CCM1–CHM mutation by genetic testing as
previously described [7], and with both genotype and phenotype
data available. Subjects were recruited through the Brain Vascular
Malformation Consortium (BVMC) study at the University of New
Mexico (UNM) and the Angioma Alliance patient advocacy group’s
DNA & Tissue Bank study as previously described [8]. The study
was approved by the local institutional review boards at UNM,
University of California, San Francisco (UCSF), and Quorum IRB
(Angioma Alliance), and by the National Institutes of Neurological
Disorders and Stroke (NINDS). Written informed consent was ob-
tained from all participants.
2.2. Clinical characteristics
Clinical assessment included information on characteristics of
presenting symptoms leading to CCM diagnosis and classiﬁed as
acute cerebral hemorrhages, seizures, focal neurological symp-
toms, and headaches using standardized guidelines [63]. Cerebral
magnetic resonance imaging (MRI) was performed for all patients
at study enrollment using a volume T1-weighted magnetization
prepared rapid gradient echo acquisition (MPRAGE, 1-mm slicereconstruction) and axial T2-weighted turbo spin echo (TSE T2), T2
gradient-recalled echo (GRE), susceptibility-weighted imaging
(SWI), and FLAIR sequences. Lesion counting was based on con-
current evaluation of axial SWI as previously described, and lesion
size was measured on TSE T2 images [7]. Three phenotypes were
used as markers of CCM1 disease severity: (1) total lesion count,
(2) large lesion count (Z5 mm), and (3) history of ICH at baseline.
In our sample, 30.3% of CCM1–CHM subjects had a history of ICH
and 90% had multiple lesions on MRI as previously reported [8],
with total lesions mean7SD of 60.17115.1 (range from 0 to 713)
and large lesions mean7SD of 4.978.7 (range from 0 to 104).
2.3. Genotyping and quality control
Blood or saliva samples were collected and genomic DNA was
extracted using standard protocols. DNA samples were genotyped
at the UCSF Genomics Core Facility using the Affymetrix Axioms
Genome-Wide LAT 1 (Axiom GW LAT) Human Array [64], as pre-
viously described [8]. This array is designed to provide optimized
genome-wide coverage of both common and rare variants in po-
pulations with West African, European, and Native American an-
cestries and consists in a total of 817,810 genetic markers, in-
cluding 813,551 SNPs and 4259 insertion/deletions (Indels). All
samples had a genotyping call rate of 97% or greater, and the two
Affymetrix Reference DNA controls were concordant, as previously
reported [8]. Further quality control steps, including sex check,
Mendelian errors and cryptic relatedness, were applied to geno-
type data using PLINK software (v1.07) before data analysis. Nei-
ther sex discordance nor Mendelian errors were identiﬁed [8].
2.4. Candidate genes and genetic markers selection
Candidate genes were selected for association studies on the
basis of their involvement in vascular responses to oxidative stress
and potential inﬂuence on major phenotypic markers of familial
CCM1 disease severity, including total lesion burden, total large
lesion burden, and history of ICH at baseline, as suggested by their
physiopathological functions and impact on cerebrovascular dis-
eases [31,43,44,53,65].
As a preliminary approach, candidate SNPs in multiple biolo-
gically relevant oxidative stress-related genes, including those
implicated in modulating vascular homeostasis and remodeling in
response to oxidative stress, were screened as putative genetic
modiﬁers of CCM disease severity in our homogeneous cohort of
Hispanic CCM1–CHM subjects, using the Axiom GW LAT Array as
previously described [8].
Based on the outcomes of our preliminary screening (data not
shown), we focused on the in-depth investigation of the two fol-
lowing gene superfamilies:
) CYP superfamily consisting of 57 genes, divided among 18 fa-
milies, encoding monooxygenase enzymes involved in the me-
tabolism of xenobiotics and endobiotics, and the production of
bioactive oxidation metabolites and reactive oxygen species
that may affect the vasculature.
) MMP superfamily consisting of 24 genes, divided among 6 fa-
milies, encoding proteolytic enzymes that degrade the ECM
scaffold, including the vascular basal lamina, enabling vascular
remodeling in response to various physiological stimuli and
pathological stresses.
The complete list of the members of CYP and MMP super-
families is given in Supplementary Table 1. CYP and MMP proteins
were classiﬁed into 18 and 6 families, respectively, according to
their structures, substrate speciﬁcity and cellular localization
[39,66]. For example, MMP families include: Collagenases (MMP-1,
Table 1
Association of CYP or MMP superfamilies and families with phenotypic markers of
CCM1 disease severity.
Genetic markers
set
N genetic
markers
P-value
Total
lesions
Large
lesions
ICH
Superfamily CYP 765 0.057 0.088 0.33
Families CYP1 16 1 0.069 1
CYP2 176 0.079 0.24 0.84
CYP3 39 0.15 0.61 0.32
CYP4 169 0.10 0.014 0.21
CYP5 80 0.60 0.058 0.56
CYP7 21 1 0.24 0.078
CYP8 47 0.014 0.10 0.61
CYP11 29 0.14 1 1
CYP17 5 0.082 1 1
CYP19 51 0.23 0.14 0.035
CYP20 11 0.22 1 1
CYP21 1 1 1 1
CYP24 27 0.045 0.32 0.24
CYP26 25 1 0.062 1
CYP27 24 0.052 0.16 0.044
CYP39 21 0.40 0.56 1
CYP46 19 0.099 0.17 0.011
CYP51 4 0.041 1 1
Superfamily MMP 357 0.33 0.54 0.37
Families Collagenases 45 0.74 0.61 0.47
Gelatinases 47 0.25 0.14 1
Stromelysins 41 0.63 1 0.007
Matrilysins 24 0.52 0.56 0.34
Membrane-type
MMPs
141 0.17 0.18 0.52
Other MMPs 59 0.17 0.73 1
P-values are corrected for the multiple markers within a set (taking account of the
LD between these genetic markers).
P-values in bold are considered statistically signiﬁcant (Pr0.017).
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-12), Matrilysins (MMP-7, -26), membrane type MMPs (MMP-14,
-15, -16, -17, -24, -25) and other MMPs (MMP-19, -20, -21, -27, -28)
(Supplementary Table 1).
Gene loci were deﬁned as 75 kb upstream and downstream of
the sequence using UCSC Genome Browser Assembly Feb. 2009
(GRCh37/hg19). The following cut-off points were used: genotype
call rate o98%, a minor allele frequency (MAF) o1%, or deviation
from Hardy-Weinberg equilibrium (Po0.001). We included 1122
genetic markers (1116 SNPs and 6 Indels) that fulﬁlled the above-
mentioned criteria and extracted the genotypes from the Axiom
GW LAT Human Array.
2.5. Statistical analysis
Residuals of log-transformed total or large lesion count were
obtained after adjustment for age at enrollment and gender (R
v2.10.1 software). To analyze the sets of genetic markers grouped
by superfamily, family or gene, we used the genetic markers “set-
based test” in PLINK v1.07 which takes account of the linkage
disequilibrium (LD) between the genetic markers and corrects P-
values for the multiple markers tested within a set using 1,000
permutations. In addition to this correction for multiple genetic
markers tested, we considered statistically signiﬁcant associations
with P-valuesr0.017 (0.050/3 phenotypes tested). The best SNP
bearing each association between CYP or MMP families or genes
and CCM1 disease severity was selected for further association
analyses: (1) linear regression to assess association between re-
siduals of log-total or large lesion count and single SNP (assuming
an additive genetic model, i.e., 0, 1, or 2 copies of the minor allele)
using STATA 12.1 statistical software (StataCorp, College Station,
Tex., USA), and (2) logistic regression to assess association be-
tween ICH and single SNP, adjusting for age at enrollment and
gender. All analyses accounted for clustering within families by
using robust standard errors, except for MMP3 rs117153070. Since
ICH analysis produced an inﬁnite estimated odds ratio (OR) for
MMP3 rs117153070, we calculated a one-sided 95% conﬁdence
interval (CI) based on the proﬁle likelihood, and derived a p-value
from the likelihood ratio test comparing models with and without
the polymorphism. To ensure familial clustering could be dis-
regarded for this speciﬁc analysis, we tested the effect of family
with a mixed-effects logistic regression model.3. Results
3.1. Association of CYP or MMP superfamilies with CCM1 disease
severity
Growing evidence suggests that oxidative stress plays an im-
portant role in CCM disease pathogenesis [16,22,24]. Moreover, it
is known that polymorphic genes related to oxidative stress and
implicated in modulating vascular homeostasis and remodeling,
including CYP and MMP genes encoding major enzymatic players
of redox metabolism and ECM remodeling, are characterized by
SNPs that confer greater susceptibility to vascular diseases
[39,47,48,61,67–69], thus representing potential genetic modiﬁers
of CCM disease severity.
In this light, we tested the possibility that genetic inter-in-
dividual variability in CYP and MMP genes inﬂuences markers of
familial CCM1 disease severity, including total lesion burden, total
large lesion burden, and history of hemorrhage at baseline. To this
end, we ﬁrst assessed the impact of the whole CYP and MMP su-
perfamilies on CCM1 disease severity by performing a genetic
marker set association analysis. The CYP superfamily, including765 genetic markers, showed a trend toward association with total
lesion count (P¼0.057) and large lesion count (P¼0.088) after
correction for multiple markers tested (Table 1). In contrast, the
MMP superfamily, including 357 genetic markers, was not asso-
ciated with phenotypic markers of disease severity.
3.2. Association of CYP or MMP families or genes with CCM1 disease
severity
We then evaluated whether the CYP and MMP families were
associated with phenotypic markers of disease severity by
grouping genetic markers by families (Supplementary Table 1). For
CYP or MMP families showing a signiﬁcant or borderline associa-
tion with CCM1 disease severity, we performed additional asso-
ciation analyses by grouping genetic markers by genes. Results are
presented in Table 2.
The CYP4 family was associated with large lesion count (P¼0.014)
(Table 1), and, among the 12 genes belonging to the CYP4 family, the
strongest association was exhibited by the CYP4F2 followed by
CYP4F11 and CYP4F12 genes (Table 2). CYP4F2, CYP4F8 and CYP4Z1
genes were also modestly associated with total lesion count (Table 2).
The CYP8 family was associated with total lesion count (P¼0.014)
(Table 1), and, of the two CYP8 genes analyzed, CYP8A1 encoding the
prostaglandin I2 (prostacyclin) synthase (PTGIS) was signiﬁcantly
associated with total lesion count (P¼0.013) (Table 2). In addition,
two families (CYP46 and MMP Stromelysins) were signiﬁcantly as-
sociated with ICH (P¼0.011 and 0.007, respectively), with CYP46A1
and MMP3 genes bearing these associations (Tables 1–2). Moreover,
CYP19, CYP24, CYP27 and CYP51 families were modestly associated
Table 2
CYP or MMP families associated with phenotypic markers of CCM1 disease severity
and association of related genes.
Genetic
markers set
N genetic
markers
P-value
Total
lesions
Large
lesions
ICH
Family CYP4 169 0.10 0.014 0.21
Genes CYP4A11 6 1 1 1
CYP4A22 5 1 1 1
CYP4B1 12 1 0.26 1
CYP4F2 13 0.027 0.007 0.16
CYP4F3 18 1 0.21 1
CYP4F8 11 0.021 1 1
CYP4F11 19 0.098 0.041 0.044
CYP4F12 28 0.086 0.030 0.16
CYP4F22 17 0.11 1 1
CYP4V2 25 0.34 1 0.35
CYP4X1 10 0.19 1 1
CYP4Z1 5 0.039 1 1
Family CYP8 47 0.014 0.10 0.61
Genes CYP8A1 (PTGIS) 39 0.013 0.12 0.56
CYP8B1 8 1 0.079 1
Family/
Gene
CYP19/CYP19A1 51 0.23 0.14 0.035
Family/
Gene
CYP24/CYP24A1 27 0.045 0.32 0.24
Family CYP27 24 0.052 0.16 0.044
Genes CYP27A1 11 1 0.036 0.041
CYP27B1 4 0.032 0.099 1
CYP27C1 9 1 1 1
Family/
Gene
CYP46/CYP46A1 19 0.099 0.17 0.011
Family/
Gene
CYP51/CYP51A1 4 0.041 1 1
Family Stromelysins 41 0.63 1 0.007
Genes MMP3 7 1 1 0.002
MMP10 19 0.39 1 0.062
MMP11 7 0.17 1 1
MMP12 8 1 1 1
P-values are corrected for the multiple markers within a set (taking account of the
LD between these genetic markers).
P-values in bold are considered statistically signiﬁcant (Pr0.017).
Table 3
SNPs bearing associations of CYP or MMP families and genes with CCM1 disease severi
Family Gene SNP MAF Variant function class Total lesion
PI 95%
CYP4 CYP4F2 rs3093088 0.13 Upstream 0.62 0.39
CYP4F8 rs28669833 0.14 Intron 1.50 1.11
CYP4F11 rs12610962 0.46 3’UTR 1.18 0.93
CYP4F12 rs11085971 0.03 Intron 0.60 0.29
CYP4Z1 rs1502924 0.11 Intron 1.61 0.98
CYP8 CYP8A1 rs5628 0.13 Synonymous (L256L) 1.79 1.13
CYP19 CYP19A1 rs72727199 0.12 Intron 0.93 0.67
CYP24 CYP24A1 rs11907350 0.03 3’UTR 0.33 0.11
CYP27 CYP27A1 rs645163 0.15 Downstream 1.02 0.69
CYP27B1 rs1048691 0.33 Downstream 0.70 0.55
CYP46 CYP46A1 rs10151332 0.46 Intron 0.96 0.73
CYP51 CYP51A1 rs2049900 0.07 Intron 0.57 0.39
Stromelysin MMP3 rs117153070 0.02 Intron 0.87 0.43
Table gives odds ratio (OR) or proportional increase (PI, or decrease if less than 1) in eithe
P-values in bold are considered statistically signiﬁcant (Pr0.017).
*The OR cannot be determined, because 100% (6/6) of heterozygous carriers have a hist
conﬁdence interval (CI) based on the proﬁle likelihood and a p-value from the likelihood
logistic regression model found no estimated family effect; hence, the model was not a
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nominal associations of CYP19A1, CYP24A1, CYP27A1, CYP27B1 and
CYP51A1 genes (Tables 1–2).
3.3. Genetic markers bearing associations between CYP or MMP fa-
milies or genes and CCM1 disease severity
We then focused on the genetic markers bearing associations of
CYP or MMP families and genes with CCM1 disease severity. As a
note, none of the six Indels tested explained the observed asso-
ciations or were individually associated with lesion counts or ICH
(Supplementary Table 2).
However, we found that an intronic SNP (rs11085971) of
CYP4F12 was mainly driving the association of CYP4 family and
CYP4F12 gene with large lesion count, and was consistently in-
dividually associated with this marker of disease severity
(Po0.001) (Table 3). Further, CYP4F2 rs3093088, CYP4F8
rs28669833 and CYP4F11 rs12610962, bearing associations of
CYPF2, CYP4F8 and CYP4F11 genes, respectively, were individually
associated with at least one disease severity phenotype (Table 3).
A synonymous SNP (rs5628, Leu256Leu) of CYP8A1 was mainly
bearing the association of CYP8 family and CYP8A1 gene with total
lesion count. Analyzed individually, this SNP was associated with
both total lesion and large lesion counts, as the minor allele car-
riers of rs5628 had 79% more total lesions (P¼0.013) and 40%
more large lesions (P¼0.006) at baseline, in comparison to non-
carriers (Table 3).
Additional SNPs were found to be individually associated with
at least one disease severity phenotype, consistently with asso-
ciations reported for CYP or MMP families and genes (Table 3). The
CYP27B1 rs1048691 and CYP51A1 rs2049900 polymorphisms were
associated with smaller total lesion counts, while the CYP27A1
rs645163 and CYP46A1 rs10151332 were associated with greater
large lesion counts and ICH (Table 3). Further, CYP19A1 rs72727199
was signiﬁcantly associated with ICH (P¼0.002), while the CYP19
family or CYP19A1 gene was modestly associated with this phe-
notype (P¼0.035) (Tables 2 and 3).
Finally, an intronic SNP (rs117153070) of MMP3, which was
mainly driving the association of Stromelysin family and MMP3
gene with ICH, was strongly associated with ICH, as all the minor
allele carriers of rs117153070 had a history of ICH (Table 3). Thus,
the results of the individual SNP analyses supported the ﬁndings
obtained with the family and gene sets.ty.
count Large lesion count ICH
C.I. P PI 95% C.I. P OR 95% C.I. P
0.99 0.046 0.71 0.54 0.94 0.019 0.82 0.39 1.70 0.59
2.02 0.009 1.08 0.85 1.36 0.52 0.80 0.43 1.48 0.47
1.50 0.16 1.21 1.04 1.40 0.014 1.94 1.19 3.16 0.007
1.26 0.18 0.49 0.40 0.59 o0.001 0.61 0.19 1.90 0.39
2.65 0.059 1.12 0.90 1.40 0.29 1.01 0.43 2.35 0.98
2.84 0.013 1.40 1.10 1.79 0.006 1.33 0.77 2.31 0.31
1.29 0.65 0.87 0.71 1.06 0.17 0.25 0.10 0.60 0.002
0.99 0.048 0.71 0.34 1.47 0.35 1.23 0.27 5.69 0.79
1.50 0.92 0.75 0.62 0.92 0.006 0.35 0.16 0.76 0.008
0.89 0.004 0.94 0.77 1.13 0.50 1.00 0.61 1.64 0.99
1.25 0.76 0.80 0.67 0.94 0.008 0.45 0.26 0.79 0.005
0.84 0.004 0.85 0.64 1.12 0.24 0.80 0.33 1.91 0.62
1.75 0.69 1.27 0.88 1.84 0.19 n/a* 8.50* 1* o0.001*
r total or large lesion count, along with 95% conﬁdence intervals as well as P-values.
ory of ICH, compared to 70% of patients all without ICH. We show a one-sided 95%
ratio test comparing models with and without the polymorphism. A mixed-effects
djusted for familial clustering.
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with CCM1 severity in Hispanic CCM1–CHM subjects were then
compared with those available in general and speciﬁc Latin po-
pulations, using the public databases from dbSNP (SNP database)
(http://www.ncbi.nlm.nih.gov/), 1000 Genomes Project global po-
pulation and HapMap MEX (Mexican Ancestry in Los Angeles)
Hispanic population. No signiﬁcant differences were found in al-
lele frequencies of SNPs reported in Table 3 in comparison to
general populations (data not shown).
3.4. Function of signiﬁcantly associated CYPs and MMPs
To gain insight into potential regulatory mechanisms through
which these CYP or MMP genes and variants might impact CCM1
disease severity, we applied complementary methods, including in
silico analyses and extensive manual review of the literature. Re-
sults are summarized in Supplementary Table 3.
We ﬁrst asked whether the encoded proteins might be grouped
into speciﬁc categories according to their functions and substrates
using the DAVID Gene Functional Classiﬁcation Tool [70]. We
found that the most signiﬁcantly associated CYPs can be grouped
into speciﬁc categories by both their endogenous substrates and
bioactive products. Indeed, they are all monooxygenases that play
key roles in the metabolism of important endogenous compounds
in the brain, including arachidonic acid (AA), AA derivatives, cho-
lesterol, steroid hormones and vitamin D3, contributing to the
production of important bioactive metabolites, such as eicosa-
noids, oxysterols, estrogens and active vitamin D3, which act as
signaling molecules in redox-related pathways and may regulate
cerebrovascular functions (Supplementary Table 3). Consistently,
we found compelling evidence in the literature that supports the
expression of CYP enzymes at the blood–brain interface, including
in cellular components of the NVUs, where they participate in the
local regulation of BBB function, vascular homeostasis and cerebral
blood ﬂow through biologically active molecules produced by the
metabolism of xenobiotics and endobiotics [40–43,71].
Speciﬁcally, members of the CYP4F subfamily have been in-
volved in the metabolism of vitamins (K1 and E), xenobiotics, in-
cluding drugs, and endobiotics, including polyunsaturated fatty
acids (PUFAs) and their derivatives [72]. In particular, there is clear
evidence that CYP4F enzymes catalyze the ω-hydroxylation of
arachidonic acid and eicosanoids, such as prostaglandins (PG),
leukotrienes (LT) and epoxyeicosatrienoic acids (EET), which act as
autocrine and paracrine factors in various biological processes af-
fecting the vasculature, including the modulation of ROS forma-
tion, inﬂammatory responses, and vascular tone, permeability and
remodeling [43,72–74].
CYP8A1 encodes the prostaglandin I2 (PGI2) synthase, which
catalyzes the conversion of prostaglandin H2 (PGH2) to PGI2
(prostacyclin), a potent vasodilator involved in local regulation of
cerebral blood ﬂow and vascular homeostasis [75–77]. Re-
markably, recent evidence demonstrates a role of prostacyclin in
KRIT1-dependent vascular endothelial cell barrier regulation [78].
CYP19A1 (also called aromatase or estrogen synthase) is ex-
pressed in major cellular components of the NVU, such as astro-
cytes and endothelial cells, and catalyzes the key aromatization
step that converts androgens into estrogens, thus playing a role in
local modulation of BBB permeability and cerebrovascular home-
ostasis mediated by sex steroid hormones [79,80]. In particular,
estrogens are known to favor vasculoprotection from oxidative
stress by inducing the upregulation of distinct proteins that exert
anti-oxidant and anti-inﬂammatory functions and contribute to
cerebrovascular homeostasis, including Mn superoxide dismutase
(SOD2) and prostacyclin synthase (CYP8A1) [79,81].
CYP51A1 (lanosterol 14α-demethylase), CYP46A1 (cholesterol
24-hydroxylase) and CYP27A1 (sterol 27-hydroxylase) are themajor CYP enzymes involved in cholesterol metabolism in the
brain. In particular, CYP51A1 is involved in cholesterol synthesis,
whereas CYP46A1 and CYP27A1 catalyze the conversion of excess
cholesterol into the oxysterols 24(S)-hydroxycholesterol (24-OHC)
and 27-hydroxycholesterol (27-OHC), respectively [82,83]. No-
tably, local excess levels of biologically active oxysterols, such as
24-OHC and 27-OHC, may trigger and sustain local oxidative stress
reactions leading to vascular dysfunctions and cerebrovascular
diseases [84–86].
CYP27A1 is also involved in the metabolism of vitamin D3,
along with CYP27B1. Indeed, these two CYP enzymes catalyze the
two key hydroxylation steps that convert the inactive form of vi-
tamin D3 (cholecalciferol) to calcifediol (25-hydroxyvitamin D3)
and calcitriol (1,25-dihydroxyvitamin D3 or active vitamin D3),
respectively [87,88]. Notably, vitamin D3 is endowed with anti-
oxidant properties in the endothelium, which may prevent per-
ipheral vascular diseases [89,90]. Consistently and importantly,
vitamin D3 supplement has been recently demonstrated to de-
crease vascular oxidative stress and CCM lesion burden in a mouse
model of CCM disease [16].
Matrix metalloproteinase-3 (MMP-3), also known as strome-
lysin-1, is a broad-spectrum extracellular matrix degrading en-
zyme that acts on collagen types II, III, IV, IX, and X, proteoglycans,
ﬁbronectin, laminin, and elastin [91]. In addition, MMP-3 can also
activate other MMPs such as MMP-1, MMP-7, and MMP-9, ren-
dering MMP-3 crucial in extracellular matrix remodeling both in
physiological and pathological processes (Supplementary Table 3).
Notably, MMP activity has been clearly implicated in focal de-
gradation of the vascular extracellular matrix underlying the onset
and progression of cerebrovascular diseases [53,92,93]. Further-
more, increased endothelial expression of MMPs has been pre-
viously suggested to contribute to the formation, enlargement and
rupture of human CCM lesions by affecting the stability of the
vascular extracellular matrix scaffold [94].
We then asked whether speciﬁc redox-related pathways were
affected by the CCM disease-associated CYP or MMP genes and
SNPs using the NCBI BioSystems database [95] and Reactome, a
curated pathway database (http://www.reactome.org/), as well as
a comprehensive review of the literature.
All CYPs are involved in biological oxidations, including oxi-
dative metabolism of endogenous and exogenous compounds by
monooxygenase activity. Moreover, CYP enzymes are among the
oxidoreductases that are potential sources of superoxide anions in
mammalian cells [38]. Indeed, compelling evidence indicates that
poor coupling of the CYP catalytic cycle may result in continuous
ROS production and consequent formation of lipid peroxidation
products, such as 4-hydroxynonenal (HNE), which in turn may
activate the redox-sensitive JNK/c-Jun signaling pathway, leading
to cellular oxidative stress [38,96]. Furthermore, CYP enzymes may
also inﬂuence redox-related pathways modulated by some of their
bioactive metabolic products, including eicosanoids, oxysterols,
steroid hormones and vitamin D3 [37,39,48,97]. Intriguingly,
whereas there is clear evidence that some CYP enzymes may act as
either regulators or targets of redox-sensitive pathways, including
the JNK/c-Jun pathway [98–100] (Supplementary Table 3), we have
previously demonstrated that the JNK/c-Jun pathway is inﬂuenced
by KRIT1 loss-of-function [22], suggesting a potential functional
connection between CYP and KRIT1 proteins.
On the other hand, there is consistent evidence that also MMP
enzymes may act as either targets or regulators of oxidative stress-
related signaling events [49,54,55]. In particular, MMP3 has been
involved in distinct redox-sensitive pathways, including PKC, PI3K/
AKT and ERK1/2 pathways [56] (Supplementary Table 3).
Importantly, none of the CCM disease-associated SNPs was
previously reported to affect speciﬁc redox related pathways. Most
of these SNPs were in non-coding regions of the candidate genes
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However, we cannot exclude a role of these non-coding SNPs in
gene regulation, as there is clear evidence that not only poly-
morphisms in the open reading frame are capable of modifying
the function of a given gene. Indeed, non-coding SNP may be
functionally relevant by affecting the promoter region [101], spli-
cing sites [102], or intronic microRNAs [103]. Accordingly, the
expression of CYP enzymes is regulated through an extremely
complex network of nuclear receptors, microRNAs and genetic/
epigenetic factors [39].
To evaluate the potential importance of these non-coding var-
iants in gene regulation, we searched for phylogenetic conserva-
tion using in silico tools, such as Ensembl Phylogenetic Context
[104]. We found that a high evolutionary conservation among
species was observed for the rs5628, rs72727199, rs645163,
rs1048691, rs2049900 and rs117153070 variants in up to 23 ver-
tebrates, including mammalian, reptile, and bird classes. Further
functional investigations using relevant human tissues and cells
are required to robustly assess the regulatory role of these non-
coding variants.4. Discussion
The results of this study indicate that oxidative stress-related
CYP and MMP genetic markers grouped by superfamilies, families,
genes or analyzed individually inﬂuence the severity of familial
CCM1 disease, as manifested by ICH and greater total or large le-
sion counts. These phenotypic markers vary widely for unknown
reasons, even among family members of similar ages harboring
the same CCM1 germline mutations, suggesting the inﬂuence of
environmental and/or other genetic factors [7,8]. Consistently, in
contrast to the wide intrafamilial variability usually observed be-
tween siblings, a great similarity of disease onset and phenotypic
markers has been found in monozygotic twins with a CCM1
germline mutation, suggesting that the expression of CCM disease
in non-twin siblings is signiﬁcantly inﬂuenced by additional ge-
netic modiﬁers [105].
In our homogeneous CCM1–CHM cohort, we reported that se-
ven CYP (CYP4, CYP8, CYP19, CYP24, CYP27, CYP46 and CYP51) and
one MMP (Stromelysins) families contribute to the wide differ-
ences observed between patients in number of total/large lesions,
or susceptibility to ICH. In particular, ten polymorphisms, includ-
ing CYP4F8 rs28669833, CYP4F11 rs12610962, CYP4F12 rs11085971,
CYP8A1 rs5628, CYP19A1 rs72727199, CYP27A1 rs645163, CYP27B1
rs1048691, CYP46A1 rs10151332, CYP51A1 rs2049900 and MMP3
rs117153070, mainly bearing the above-mentioned associations,
were individually signiﬁcantly associated with at least one marker
of CCM1 disease severity. Thus, our study supports a role of
oxidative stress-related genetic risk factors in predicting CCM1
disease outcomes.
Our ﬁndings are consistent with the expression of the identi-
ﬁed CYP genes at the blood–brain interface, where they contribute
to the production of many bioactive metabolites that affect vas-
cular tone and homeostasis and BBB stability, including oxidative
derivatives of arachidonic acid and cholesterol, such as eicosanoids
and oxysterols, steroid hormones and vitamin D3 [36,40–
43,71,106]. Further support is provided by compelling evidence
that CYP activity is associated with enhanced local formation of
ROS and lipid peroxidation products, which may alter redox sig-
naling pathways and cause oxidative stress-mediated vascular
dysfunctions [37,38,71,96,97,107]. Importantly, they are also con-
sistent with previous studies reporting the association of CYP ge-
netic polymorphisms with different degrees of susceptibility to
various cerebrovascular diseases [44,46]. In turn, this may reﬂect
the highly polymorphic nature and signiﬁcant inter-individual andinter-tissue variability in the expression and activity of CYP en-
zymes, and the consequent variability in the occurrence of local
oxidative stress events [39,48,108].
Speciﬁcally, our ﬁndings that SNPs in CYP8A1, CYP4F8, CYP4F11
and CYP4F12 are associated with at least one marker of CCM1
disease severity are consistent with the established role of these
enzymes in the production of eicosanoids, such as prostaglandins
(PGs), leukotrienes (LTs) and epoxyeicosatrienoic acids (EETs),
which are long recognized as key regulators of local cere-
brovascular functions, as well as therapeutic targets for cere-
brovascular diseases [43,72–74]. Accordingly, genetic variations in
CYP enzymes involved in eicosanoid pathways are generally con-
sidered one of the determinants of individual susceptibility to
vascular diseases, including cerebrovascular diseases [39,48],
supporting the possibility that inter-individual variations in local
eicosanoid metabolism and signaling inﬂuence CCM1 disease se-
verity. Indeed, consistent with its potential modulating role in
CCM1 disease, the rs5628 polymorphism of the CYP8A1 gene,
which encodes the prostacyclin (PGI2) synthase, has been pre-
viously associated with genetic predisposition to hemorrhagic
stroke in Korean population [109]. Moreover, further support is
provided by recent evidence demonstrating a role of prostacyclin
in KRIT1-dependent vascular endothelial cell barrier regulation
[78].
The association between CYP19A1 rs72727199 and ICH is con-
sistent with the important role of CYP19A1 (estrogen synthase) in
the local modulation of BBB permeability and cerebrovascular
homeostasis mediated by sex steroid hormones [79,80]. Indeed,
CYP19A1 is expressed at the NVU and catalyzes a key step in the
biosynthesis of estrogens, which are known to favor vasculopro-
tection from oxidative stress by increasing cerebrovascular levels
of proteins endowed with antioxidant and anti-inﬂammatory
properties, including SOD2 and prostacyclin synthase (CYP8A1)
[79,81]. Intriguingly, whereas there is evidence that deﬁciencies in
estrogen-mediated regulation of cerebrovascular homeostasis may
contribute to an increased risk of cerebral aneurysm pathogenesis
and rupture [110,111], it has been reported that risk of recurrent
ICH due to CCM is greater for women than men [63], suggesting
that cerebrovascular levels of sex hormones may have a role in the
variable expression of CCM disease.
The association of CYP46A1 rs10151332 and CYP27A1 rs645163
polymorphisms with both large CCM lesion count and suscept-
ibility to ICH is consistent with a substantial body of evidence
indicating that variations in CYPs involved in cholesterol meta-
bolism in the brain, such as the cholesterol 24-hydroxylase
CYP46A1 and the sterol 27-hydroxylase CYP27A1, can lead to local
excess levels of biologically active 24-OHC and 27-OHC oxysterols
[84,85,112–115]. Indeed, local accumulation of these cholesterol
oxidation derivatives can trigger and sustain local oxidative stress
and inﬂammatory reactions that contribute to distinct human
disorders, including cerebrovascular diseases [83,86,116]. Accord-
ingly and importantly, markers of cholesterol metabolism in the
brain, including the 24-OHC and 27-OHC oxysterols, showed
strong associations with cerebrovascular diseases [86].
CYP27A1 is also involved in the metabolism of vitamin D3
along with CYP27B1, acting as vitamin D3 25-hydroxylase and 25-
hydroxyvitamin D3 1α-hydroxylase, respectively [87,88,117]. Con-
sistent with a potential impact on CCM disease severity of genetic
variations in CYP enzymes involved in vitamin D3 metabolism,
including the identiﬁed CYP27A1 rs645163 and CYP27B1
rs1048691 SNPs, recent in vitro and in vivo studies have demon-
strated the effectiveness of vitamin D3 in decreasing vascular
oxidative stress and CCM lesion burden in a mouse model of CCM
disease [16]. Accordingly, vitamin D3 is endowed with antioxidant
properties in the endothelium, and may prevent peripheral vas-
cular diseases [89,90].
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MMP3 rs117153070 polymorphism and ICH, which is in line with
previous studies reporting associations between MMPs and ICH in
human [65]. Accordingly, MMP-related genetic variations, includ-
ing SNPs, may contribute to heterogeneity in vascular remodeling
and consequent presentation and natural history of cere-
brovascular diseases [53,93]. Indeed, there is compelling evidence
that polymorphisms in MMP genes, including MMP3, may inﬂu-
ence inter-individual differences in susceptibility to the onset and
severity of cerebral aneurysms [57], brain arteriovenous mal-
formations [58–60], ischemic white matter injury [118], and
Moyamoya disease [62]. Furthermore and consistent with a po-
tential impact of MMP genetic variations on CCM disease, in-
creased endothelial expression of MMPs has been previously ob-
served in human CCM lesions and suggested to contribute to their
formation, enlargement and rupture by affecting the stability of
the vascular extracellular matrix scaffold [94]. In addition, whereas
there is evidence that polymorphisms in MMP genes may inﬂu-
ence cerebral small vessel disease associated with white matter
lesions [68], an increased frequency of white matter lesions among
familial cases of CCM disease has been recently reported [119].
Some of the identiﬁed SNPs were concomitantly associated
with two phenotypic makers of CCM disease severity, including
CYP8A1 rs5628, which was associated with both total and large
number of CCM lesions, and CYP4F11 rs12610962, CYP27A1
rs645163 and CYP46A1 rs10151332, which were associated with
large lesion count and susceptibility to ICH phenotypes. However,
no signiﬁcant concomitant association with all three phenotypic
markers of CCM disease severity was observed, suggesting that
multiple genetic risk factors contribute to the distinct most severe
phenotypes of the disease.
The study was centered on an ethnically homogeneous cohort
of 188 Hispanic CCM patients carrying the founder KRIT1/CCM1–
CHM mutation, which avoided confounding factors due to differ-
ences in population genetic structure and disease-causing muta-
tion. Furthermore, it was based on a genetic marker set association
analysis, which is more powerful than testing each genetic marker
individually [120,121]. Despite some limitations, including the
limited ethnic group and sample size of our CCM1 cohort and the
fact that our selection of common genetic markers cannot exclude
the possibility for rare functional variants in these families to in-
ﬂuence the severity of CCM1 disease, our study has the important
value of opening a novel avenue for future basic and translational
research in the ﬁeld of CCM disease. Indeed, our experimental
outcomes prompt future replication studies with independent and
random cohorts of CCM subjects to verify whether the genetic
modiﬁers of CCM1 disease severity identiﬁed in our KRIT1/CCM1–
CHM cohort are replicated in subjects affected by other forms of
CCM disease, including sporadic forms and familial forms linked to
different mutations in any CCM gene, as well as across different
ethnic groups. The conﬁrmation and extension of our results
might lead to the recognition of subsets of CCM patients who are
predisposed to develop the most severe disease phenotypes, in-
cluding ICH, offering the opportunity to prevent these events and
related complications, and improve outcomes. Furthermore, our
ﬁndings pave the way for future basic research investigations
aimed at addressing the role of speciﬁc CYP enzymes and meta-
bolites in CCM disease pathogenesis and severity, providing a
novel useful framework for a better understanding of pathogenic
mechanisms, the identiﬁcation of new diagnostic, prognostic and
predictive biomarkers, and the development of speciﬁc and ef-
fective preventive and therapeutic strategies.
5. Conclusions
This study furthers research into genetic modiﬁers in CCM1disease by studying genetic markers in candidate oxidative stress-
related gene families at multiple levels of information: super-
families, families, and individual genetic markers. Our results
suggest that genetic variability within CYP4, CYP8, CYP19, CYP24,
CYP27, CYP46, CYP51 and the MMP Stromelysins families may
inﬂuence the severity of CCM1 disease and could serve as pre-
dictors of CCM1 disease outcomes. These ﬁndings most probably
reﬂect the important role of the identiﬁed CYP and MMP enzymes
in vascular homeostasis through the regulation of eicosanoid and
cholesterol metabolism, and extracellular matrix remodeling, re-
spectively, suggesting that these biological processes contribute to
the heterogeneity in the presentation and natural history of CCM
disease.Funding
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